Letermovir

Cytomegalovirus DNA Terminase Complex Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Letermovir is an onp drug in the Cytomegalovirus DNA Terminase Complex Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Cytochrome P450 2C19 Inducers, Cytochrome P450 2C8 Inhibitors and Cytochrome P450 2C9 Inducers. DrugCentral lists 1 molecular target, including TRM1|TRM2|TRM3. Recorded indications include Cytomegalovirus infection.

• Approval status: onp (first approved 2017 by the FDA).
• Drug class: Cytomegalovirus DNA Terminase Complex Inhibitor.
• Mechanism of action: Cytochrome P450 2C19 Inducers; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2C9 Inducers.
• Molecular targets: TRM1|TRM2|TRM3 (1 listed in DrugCentral).
• Indications: Cytomegalovirus infection.
• ATC code: J05AX18 (Other antivirals).
• Molecular formula: C29H28F4N4O4; molecular weight 572.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Cytomegalovirus infection

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 2C19 Inducers; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2C9 Inducers; Cytochrome P450 3A Inhibitors; DNA Terminase Complex Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors
• Established pharmacologic class: Cytomegalovirus DNA Terminase Complex Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
DNA terminase complex	TRM1|TRM2|TRM3	inhibitor	EC50 8.68

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2018-03-23	PMDA	—	MSD KK
2018-01-08	EMA	—	Merck Sharp & Dohme Limited	Yes
2017-11-08	FDA	—	MERCK SHARP DOHME	Yes

ATC classification

ATC code	Therapeutic hierarchy
J05AX18	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Other antivirals

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• Swissmedic label: SLCO1B1, UGT1A1 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cytomegalovirus infection reactivation	836.8
Off label use	496.9
Encephalitis cytomegalovirus	381.0
Epstein-Barr viraemia	307.3
Cystitis haemorrhagic	297.2
BK virus infection	283.5
Cytomegalovirus infection	250.5
Nephropathy toxic	207.4
Pathogen resistance	205.8
Cytomegalovirus viraemia	202.1
Pancytopenia	201.6
Drug resistance	197.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Letermovir is on its molecule page.

• Molecular formula: C₂₉H₂₈F₄N₄O₄
• Molecular weight: 572.56 g/mol
• CAS number: 917389-32-3
• InChIKey: FWYSMLBETOMXAG-QHCPKHFHSA-N
• PubChem CID: 45138674

COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=C(OC)C=CC(=C1)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Letermovir used for?

DrugCentral lists the following indications for Letermovir: Cytomegalovirus infection.

How does Letermovir work?

Letermovir is classified as Cytochrome P450 2C19 Inducers, Cytochrome P450 2C8 Inhibitors and Cytochrome P450 2C9 Inducers; its molecular targets in DrugCentral include TRM1|TRM2|TRM3 (inhibitor).

When was Letermovir first approved?

Letermovir was first approved by the FDA in 2017.

What drug class does Letermovir belong to?

Letermovir is in the Cytomegalovirus DNA Terminase Complex Inhibitor class.

What is the chemical formula of Letermovir?

Letermovir has the molecular formula C29H28F4N4O4 and a molecular weight of 572.56 g/mol.

Sources

• DrugCentral drug card 5262 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1241951 — compound record and bioactivity
• PubChem CID 45138674 — chemical identifiers
• DrugBank DB12070 — drug record
• FDA UNII 1H09Y5WO1F — substance identity
• DailyMed: FDA labels for Letermovir — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.